Inanovate’s Breast Cancer Solutions

Inanovate has developed a patented blood analysis system (the Bio-ID) that improves the cost, accessibility, and accuracy of diagnostic tests. The first application of the Bio-ID is a new blood test with 2 clinical Intended Uses:

Use 1: To improve the accuracy of mammography for breast cancer screening: Approximately 10% of the 37 million screening mammograms performed annually in the US require follow-up testing to resolve the diagnosis, yet more than 95% of these are ‘false positives’ in which no cancer is detected. The economic cost of false-positive mammograms is ~$4 billion, and >1 million women are exposed to risks associated with subsequent diagnostics. Inanovate seeks to address this issue through a simple, inexpensive blood test, that will provide additional data on a patients cancer risk to help inform clinicians whether follow up procedures are necessary.

Use 2: To detect breast cancer recurrence at a stage when it may still be cured: Presently, over 40,000 women die every year from breast cancer in the US alone, the majority following a recurrence. That’s over 100 women dying each day. Studies have shown that early detection of recurrence can improve survival rates by up to 50%. Inanovate seeks to address this issue through a simple, inexpensive blood test that will track a patients’ response to therapy, and will also identify recurrence at its earliest stage, before physical symptoms arise. To date, three 400 patient studies have been completed with our clinical partner Sanford Health. These have correctly identified over 8 in 10 cases of breast cancer, with only 3 in 10 false positives. We are now working to optimize performance and prepare for extended clinical trials as we progress towards FDA Pre-Market approval

Inanovate is now advancing through an extended 1,000 patient trial via our partnership with Sanford Health. If you would like to know how to get involved in helping advance this break-through test into clinical practice, and/or you would like further information on Inanovate, including investment opportunities or partnering opportunities, please contact Inanovate at: enquiries@inanovate.com.